HLS Therapeutics Inc (DE:74D)
FRANKFURT:74D

HLS Therapeutics Inc (DE:74D) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

74D Analyst Ratings

Moderate Buy
2Ratings
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
HLS
Therapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

74D Stock 12 Months Forecast

Average Price Target

€17.61
▲(157.09% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for HLS Therapeutics Inc in the last 3 months. The average price target is €17.61 with a high forecast of €17.61 and a low forecast of €17.61. The average price target represents a 157.09% change from the last price of €6.85.
Highest Price Target€17.61Average Price Target€17.61Lowest Price Target€17.61
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Raymond James
€19.92
Buy
190.84%
Upside
Reiterated
HLS Therapeutics is our Best Pick, says Raymond JamesBy Jayson MacLean Published on July 27, 2022 Last Updated on July 28, 2022 Filed under: All posts , Analysts , Pharma and Biotech Stock: hlsHLS Therapeutics is our Best Pick, says Raymond James
Bloom Burton
€15.65
Buy
128.52%
Upside
Reiterated
We expect that similar agreements with the remaining provinces including BC (14%) and Alberta (12%) will occur over the next several weeks to months. Reimbursement, per the pCPA LOI, will be available for patients with established cardiovascular disease and is for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non- fatal stroke, coronary revascularization or hospitalization for unstable angina).
Canaccord Genuity
€19.21
Buy
180.46%
Upside
Reiterated
HLS Therapeutics (HLS:CN) (HLTRF) PT Lowered to Cdn$27 at Canaccord GenuityCanaccord Genuity analyst Tania Gonsalves lowered the price target on HLS Therapeutics (HLS:CN) (OTC: HLTRF) to Cdn$27.00 (from Cdn$30.50) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

74D Financial Forecast

74D Earnings Forecast
Next quarter’s earnings estimate for 74D is -€0.08 with a range of -€0.11 to -€0.02. The previous quarter’s EPS was -€0.14. 74D beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 46.97% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.
Next quarter’s earnings estimate for 74D is -€0.08 with a range of -€0.11 to -€0.02. The previous quarter’s EPS was -€0.14. 74D beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 46.97% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.
74D Sales Forecast
Next quarter’s sales forecast for 74D is €16.73M with a range of €15.95M to €17.78M. The previous quarter’s sales results were €14.59M. 74D beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 70.00% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.
Next quarter’s sales forecast for 74D is €16.73M with a range of €15.95M to €17.78M. The previous quarter’s sales results were €14.59M. 74D beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 70.00% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.
74D Analyst Recommendation Trends
In the current month, 74D has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The 74D average analyst price target in the past 3 months is €17.61
In the current month, 74D has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The 74D average analyst price target in the past 3 months is €17.61

74D Stock Forecast FAQ

What is DE:74D’s average 12-month price target, according to analysts?
Based on analyst ratings, HLS Therapeutics Inc’s 12-month average price target is €17.61.
    What is DE:74D’s upside potential, based on the analysts’ average price target?
    HLS Therapeutics Inc has 157.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DE:74D a Buy, Sell or Hold?
          HLS Therapeutics Inc has a conensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is HLS Therapeutics Inc’s price target?
            The average price target for HLS Therapeutics Inc is €17.61. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is €17.61 ,the lowest forecast is €17.61. The average price target represents 157.09% Increase from the current price of €6.85.
              What do analysts say about HLS Therapeutics Inc?
              HLS Therapeutics Inc’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis